Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2009, Article ID 591704, 9 pages
http://dx.doi.org/10.1155/2009/591704
Research Article

Tumor Necrosis Factor Receptor Superfamily, Member 1B Haplotypes Increase or Decrease the Risk of Inflammatory Bowel Diseases in a New Zealand Caucasian Population

1Discipline of Nutrition, The University of Auckland, Private Bag 92019, Auckland 1023, New Zealand
2Nutrigenomics New Zealand, New Zealand
3Department of Gastroenterology, Christchurch Hospital, Christchurch 8011, New Zealand
4Department of Medicine, University of Otago Christchurch, New Zealand
5Crop and Food Research, Mosgiel 9053, New Zealand
6AgResearch Limited, Mosgiel 9053, New Zealand

Received 3 October 2008; Accepted 2 February 2009

Academic Editor: Robert Wyllie

Copyright © 2009 Lynnette R. Ferguson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Inflammatory bowel diseases (IBDs) comprising Crohn disease (CD) and ulcerative colitis (UC) are chronic inflammatory conditions with polygenic susceptibility. Interactions between TNF-alpha and TNF-alpha receptor play a fundamental role in inflammatory response. This study investigates the role that selected single nucleotide polymorphisms (SNPs) and haplotypes in the TNF-alpha receptor (TNSFRSF1B) gene play in the risk of IBD in a New Zealand Caucasian population. DNA samples from 388 CD, 405 UC, 27 indeterminate colitis patients, and 293 randomly selected controls, from Canterbury, New Zealand were screened for 3 common SNPs in TNSFRSF1B: rs1061622 ( ), rs1061624 ( ), and rs3397 ( ), using TaqMan technologies. Carrying the rs1061624 variant decreased the risk of UC in the left colon (OR 0.73, 95%  –1.00) and of being a smoker at diagnosis (OR 0.62; 95%  –0.96). Carrying the rs3397 variant decreased the risk of penetrating CD (OR 0.62, 95%  –0.95). Three marker haplotype analyses revealed highly significant differences between CD patients and control subjects ( , , ) and UC cases and controls ( , , ). We conclude that carrying a 3-marker haplotype in the TNSFRSF1B gene may increase (e.g., haplotype of GGC was 2.9-fold more in the CD or UCpatients) or decrease (e.g., TGT was 0.47-fold less in UC patients) the risk of IBD in a New Zealand Caucasian population.